Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > CamAPS Liberty®: behind the headlines
The CamAPS FX app houses the algorithm used in the ‘mylife Loop’ which consists of the ‘myLife YpsoPump’ insulin pump and a compatible continuous glucose monitor. ‘CamAPS Liberty’ is a new feature that will be available in this system. This feature is designed to temporarily remove the stress of carbohydrate counting and remove the relentless nature of T1D for periods when life feels overwhelming. This feature can be turned on in the app, and insulin delivery will be adjusted automatically based on glucose levels without the need for mealtime announcement.
CamAPS Liberty feature uses a more proactive version of hybrid closed loop (HCL) algorithm. It does this by anticipating and responding to glucose changes while maintaining established safety boundaries which are pre-set in the pump device.
When CamAPS Liberty is first turned on, all users need to watch a short training video to make sure they know how to use this new feature. The app contains a ‘block’ feature, to prevent accidental use of any of its programmes, and a remote monitoring via the ‘Companion’ function to allow parents and caregivers to monitor glucose and insulin levels when their loved one is not with them. CamAPS Liberty has not been studied in pregnancy or in children under 13 years of age and is therefore not recommended for use in these populations.
CamAPS Liberty has not been studied in pregnancy or in children under 13 years of age and is therefore not recommended for use in these populations.
There is no specific time limitation built into the CamAPS Liberty feature. It can be used as much or as little as an individual user selects, meaning it can be used all the time or not at all. This should be discussed with your diabetes team.
CamAPS Liberty has been designed to be used as part of your wider diabetes treatment plan, developed together with your clinical team. Each treatment plan is different depending on needs, routines and circumstances. If there’s uncertainty about how they use CamAPS Liberty, they should consult their care team.
In HCL systems, an insulin pump communicates with a continuous glucose monitor (CGM), adjusting basal insulin levels to accommodate for rising blood glucose levels. There is still a requirement to administer bolus insulin for meals.
FCL systems are designed to remove the requirement to bolus insulin for meals. Miscalculation of mealtime carbohydrates and bolus timing contributes to both high and low blood glucose levels for people with T1D, and these miscalculations can have detrimental short and long-term effects. The CamAPS Liberty function is an example of an FCL system.
There is a multitude of ongoing research into FCL systems, some of which was presented at ATTD in 2026, including the AIDANET trial, which is funded by Breakthrough T1D. This trial is ongoing and recruiting in the United States.
Breakthrough T1D is funding another trial in Canada to see if taking other drugs such as dapagliflozin or glucagon, whilst on a FCL system can help people’s blood glucose management and prevent hyperglycaemia after meals. One of these drugs is called tirzepatide, which is a class of drugs called GLP-1 receptor agonists. You may have heard of it referred to as the brand name Mounjaro or Zepbound. The end goal of this study is to see if tirzepatide can assist in controlling post-meal glucose spikes, allowing FCL systems to work continuously.
There are two significant trials, called CLEAR and CLOSE-IT, which looked at FCL system testing and showed significant quality of life improvements for those who took part.
All participants in CLEAR had improved sleep, improved mood and freed up mental capacity. Those involved even noted how sad they were to stop the trial and have to go back to regular carb counting, as this trial gave them freedom. The time in range achieved in this trial was better than users without the closed loop system.
The CLOSE-IT trial published results in 2026. Results from this study showed that the time in range for FCL and HCL were similar. In the trial, use of a FCL system was safe and achieved favourable glycaemic outcomes for most people that were similar to those seen in those using the HCL system.
CLOSE-IT was the largest study to date to demonstrate the effectiveness of FCL in adults with T1D. These results provide new knowledge that FCL is a legitimate option for the management of T1Ds. This work was proudly funded by Breakthrough T1D.
With ongoing research into FCL systems, and with a FCL option available now through CamAPS Liberty, there is a growing amount of data in support of these systems for people with T1D, even though there is a a lot of research still to be done.
There needs to be strict testing on these systems and enough data from clinical trials to support them being available for constant use, not just temporarily. With ongoing global clinical trials still running, there will be updates on FCL systems in the future.
Find out about the global research we're funding to find cures and better treatments for T1D.
Get information and advice about living well with type 1.
Join our mission to find cures for T1D and, until then, make life better for people living with it.
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
Highlights from an extraordinary year in type 1 diabetes (T1D) research, treatment, advocacy and policy.
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
